Ascendis Pharma A/S (NASDAQ:ASND) Given New $216.00 Price Target at Bank of America

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective raised by Bank of America from $201.00 to $216.00 in a report released on Monday morning,Benzinga reports. Bank of America currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on ASND. Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an “outperform” rating in a research report on Friday, May 2nd. Evercore ISI boosted their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an “overweight” rating in a report on Friday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. Finally, Royal Bank of Canada boosted their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus price target of $217.73.

Ascendis Pharma A/S Trading Up 0.1%

Shares of ASND stock opened at $173.15 on Monday. The company has a market cap of $10.56 billion, a P/E ratio of -24.39 and a beta of 0.37. The firm has a fifty day moving average price of $159.37 and a 200 day moving average price of $147.11. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors have recently added to or reduced their stakes in ASND. RA Capital Management L.P. boosted its stake in shares of Ascendis Pharma A/S by 1.7% during the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock worth $1,602,474,000 after acquiring an additional 168,752 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S by 2.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company’s stock worth $702,538,000 after purchasing an additional 114,167 shares during the last quarter. Artisan Partners Limited Partnership boosted its position in Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company’s stock worth $612,689,000 after purchasing an additional 39,309 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Ascendis Pharma A/S by 4.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company’s stock valued at $602,910,000 after purchasing an additional 193,688 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its holdings in Ascendis Pharma A/S by 12.0% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock valued at $475,970,000 after purchasing an additional 328,278 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.